BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Arroyo J, Escobar-Zarate D, Wells HH, Constans MM, Thao K, Smith JM, Sieben CJ, Martell MR, Kline TL, Irazabal MV, Torres VE, Hopp K, Harris PC. The genetic background significantly impacts the severity of kidney cystic disease in the Pkd1RC/RC mouse model of autosomal dominant polycystic kidney disease. Kidney Int 2021;99:1392-407. [PMID: 33705824 DOI: 10.1016/j.kint.2021.01.028] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Li XW, Ran JH, Zhou H, He JZ, Qiu ZW, Wang SY, Wu MN, Zhu S, An YP, Ma A, Li M, Quan YZ, Li NN, Ren CQ, Yang BX. 1-Indanone retards cyst development in ADPKD mouse model by stabilizing tubulin and down-regulating anterograde transport of cilia. Acta Pharmacol Sin 2023;44:406-20. [PMID: 35906293 DOI: 10.1038/s41401-022-00937-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Tran Nguyen Truc L, Matsuda S, Takenouchi A, Tran Thuy Huong Q, Kotani Y, Miyazaki T, Kanda H, Yoshizawa K, Tsukaguchi H. Mechanism of cystogenesis by Cd79a-driven, conditional mTOR activation in developing mouse nephrons. Sci Rep 2023;13:508. [PMID: 36627370 DOI: 10.1038/s41598-023-27766-2] [Reference Citation Analysis]
3 Nguyen DT, Kleczko EK, Dwivedi N, Monaghan MT, Gitomer BY, Chonchol MB, Clambey ET, Nemenoff RA, Klawitter J, Hopp K. The tryptophan-metabolizing enzyme indoleamine 2,3-dioxygenase 1 regulates polycystic kidney disease progression. JCI Insight 2023;8:e154773. [PMID: 36422996 DOI: 10.1172/jci.insight.154773] [Reference Citation Analysis]
4 Pang X, He X, Qiu Z, Zhang H, Xie R, Liu Z, Gu Y, Zhao N, Xiang Q, Cui Y. Targeting integrin pathways: mechanisms and advances in therapy. Signal Transduct Target Ther 2023;8:1. [PMID: 36588107 DOI: 10.1038/s41392-022-01259-6] [Reference Citation Analysis]
5 Swenson-fields KI, Ward CJ, Lopez ME, Fross S, Heimes Dillon AL, Meisenheimer JD, Rabbani AJ, Wedlock E, Basu MK, Jansson KP, Rowe PS, Stubbs JR, Wallace DP, Vitek MP, Fields TA. Caspase-1 and the inflammasome promote polycystic kidney disease progression. Front Mol Biosci 2022;9. [DOI: 10.3389/fmolb.2022.971219] [Reference Citation Analysis]
6 Zhou X, Torres VE. Emerging therapies for autosomal dominant polycystic kidney disease with a focus on cAMP signaling. Front Mol Biosci 2022;9:981963. [DOI: 10.3389/fmolb.2022.981963] [Reference Citation Analysis]
7 Zhang Y, Daniel EA, Metcalf J, Dai Y, Reif GA, Wallace DP. CaMK4 overexpression in polycystic kidney disease promotes mTOR-mediated cell proliferation. J Mol Cell Biol 2022;14. [PMID: 36002021 DOI: 10.1093/jmcb/mjac050] [Reference Citation Analysis]
8 Nguyen DT, Kleczko EK, Dwivedi N, Gitomer BY, Chonchol MB, Clambey ET, Nemenoff RA, Klawitter J, Hopp K. The Tryptophan Metabolizing Enzyme Indoleamine 2,3-Dioxygenase 1 Regulates Polycystic Kidney Disease Progression.. [DOI: 10.1101/2022.05.04.490641] [Reference Citation Analysis]
9 Ajiri R, Burgmaier K, Akinci N, Broekaert I, Büscher A, Dursun I, Duzova A, Eid LA, Fila M, Gessner M, Gokce I, Massella L, Mastrangelo A, Miklaszewska M, Prikhodina L, Ranchin B, Ranguelov N, Rus R, Sever L, Thumfart J, Weber LT, Wuehl E, Yilmaz A, Dötsch J, Schaefer F, Liebau MC. Phenotypic Variability in Siblings with Autosomal Recessive Polycystic Kidney Disease. Kidney International Reports 2022. [DOI: 10.1016/j.ekir.2022.04.095] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Kleczko EK, Nguyen DT, Marsh KH, Bauer CD, Li AS, Furgeson SB, Gitomer BY, Chonchol MB, Clambey ET, Zimmerman KA, Nemenoff RA, Hopp K. Immune Checkpoint Activity Regulates Polycystic Kidney Disease Progression.. [DOI: 10.1101/2022.04.24.489306] [Reference Citation Analysis]
11 Bufi R, Korstanje R. The impact of genetic background on mouse models of kidney disease. Kidney International 2022. [DOI: 10.1016/j.kint.2022.03.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
12 Hopp K, Catenacci VA, Dwivedi N, Kline TL, Wang W, You Z, Nguyen DT, Bing K, Poudyal B, Johnson GC, Jackman MR, Miller M, Steele CN, Serkova NJ, MacLean PS, Nemenoff RA, Gitomer B, Chonchol M, Nowak KL. Weight loss and cystic disease progression in autosomal dominant polycystic kidney disease. iScience 2022;25:103697. [PMID: 35059607 DOI: 10.1016/j.isci.2021.103697] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Yanda MK, Tomar V, Cole R, Guggino WB, Cebotaru L. The Mitochondrial Ca2+ import complex is altered in ADPKD. Cell Calcium 2022;101:102501. [DOI: 10.1016/j.ceca.2021.102501] [Reference Citation Analysis]
14 Qiu Z, He J, Shao G, Hu J, Li X, Zhou H, Li M, Yang B. Obacunone Retards Renal Cyst Development in Autosomal Dominant Polycystic Kidney Disease by Activating NRF2. Antioxidants (Basel) 2021;11:38. [PMID: 35052542 DOI: 10.3390/antiox11010038] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
15 Onuchic L, Padovano V, Schena G, Rajendran V, Dong K, Gresko NP, Shi X, Shen H, Somlo S, Caplan MJ. The C-terminal tail of polycystin-1 suppresses cystic disease in a mitochondrial enzyme-dependent fashion.. [DOI: 10.1101/2021.12.21.473680] [Reference Citation Analysis]
16 Zhang X, Li LX, Ding H, Torres VE, Yu C, Li X. Ferroptosis Promotes Cyst Growth in Autosomal Dominant Polycystic Kidney Disease Mouse Models. J Am Soc Nephrol 2021;32:2759-76. [PMID: 34716241 DOI: 10.1681/ASN.2021040460] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
17 Yanda MK, Cebotaru L. VX-809 mitigates disease in a mouse model of autosomal dominant polycystic kidney disease bearing the R3277C human mutation. FASEB J 2021;35:e21987. [PMID: 34662459 DOI: 10.1096/fj.202101315R] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]